Here’s How Much $1000 Invested In AstraZeneca 5 Years Ago Would Be Worth Today
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 5.5% on an annualized basis producing an average annual return of 15.24%. Currently, AstraZeneca has a market capitalization of $189.43 billion.
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
The regulatory authority in Japan has approved AstraZeneca plc’s (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination for…
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial
Additional readouts from Valneva SE’s (NASDAQ:VALN) pivotal VLA2001-301 “Cov-Compare” trial of COVID-19 vaccine VLA2001 showed persistent and first positive heterologous booster…
AstraZeneca Reported Farxiga Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients With Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial
Detailed results from the DELIVER Phase III trial showed AstraZeneca's Farxiga (dapagliflozin) significantly reduced the composite of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (EF), compared to placebo.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F…
Back-To-Back Three Japanese Approvals For AstraZeneca’s Rare Disease Treatments
The Japan regulatory authority has approved AstraZeneca Plc (NASDAQ:AZN) and Merck Co Inc’s (NYSE:MRK) Lynparza (olaparib) for the adjuvant treatment of patients with…
AstraZeneca Announced Ultomiris Approved in Japan for gMG
Ultomiris (ravulizumab) has been approved in Japan for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy (IVIg) or plasmaphaeresis.